Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to
see how well it works in finding cancer in patients with pancreatic cancer who are undergoing
surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and
IRDye800CW, an investigational dye that can be seen using a special camera.
Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in
patients with pancreatic cancer.